CTIS2023-506163-34-00Active, not recruitingPhase 1
BIO-PERTUZ-301
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
- Biocon Biologics UK Limited
- Enrollment
- 382
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 to 65+ (—)
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Similar Trials
Recruiting
Phase 1
A study to characterize the pharmacokinetic profile of norucholic acid (NCA) in patients with primary sclerosing cholangitis (PSC)CTIS2023-507027-37-00Dr. Falk Pharma GmbH43
Recruiting
Phase 1
A clinical trial to learn how an investigational drug (norucholic acid) is absorbed, distributed, broken down, and removed from the body when given to people with kidney problemsCTIS2023-505862-27-00Dr. Falk Pharma GmbH48
Recruiting
Phase 1
A phase 1 study of oral Debio 0123 in combination with carboplatin in patients with advanced solid tumorsPatients with tumorsMedDRA version: 21.1Level: LLTClassification code: 10065147Term: Malignant solid tumor Class: 10029104MedDRA version: 21.1Level: LLTClassification code: 10065252Term: Solid tumor Class: 10029104CTIS2024-510984-52-00Debiopharm International SA115
Recruiting
Phase 1
An open-label, phase I/II study of T3P-Y058-739, a genetically-modified strain of the bacterium Yersinia enterocolitica, in patients with advanced solid tumoursCTIS2023-504199-19-00T3 Pharmaceuticals AG100
Recruiting
Phase 1
A study of the safety and tolerability of timolol administration by an eye implant in patients with glaucomaGlaucomaMedDRA version: 20.0Level: LLTClassification code: 10030856Term: Open-angle glaucoma Class: 10015919MedDRA version: 26.0Level: PTClassification code: 10048867Term: Pseudophakia Class: 10042613CTIS2024-511254-51-00Eyed Pharma18